# Engineered immune surveillance: long-lived programmed immune cells that patrol for early cancer

Source: https://onco.cc/ideas/idea-moon-engineered-immune-surveillance/  
OnCo record `idea-moon-engineered-immune-surveillance` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

For people at very high cancer risk, install a small population of engineered immune cells that live for years and destroy cells showing early cancer signals before a tumour forms.

## Summary

Immune surveillance normally eliminates most incipient tumours; carriers of BRCA, Lynch or TP53 mutations and people with clonal haematopoiesis face lifelong high risk. Advances in memory stem T cell engineering, logic-gated receptors responsive to stress ligands or shared neoantigens, and safety switches make a persistent, low-level engineered surveillance population conceivable. The proposal is a research programme to define target ligands of pre-malignant cells, engineer persistent gated cells with off-switches, and demonstrate prevention in genetically engineered mouse models before first-in-human studies in the highest-risk carriers.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Engineered surveillance cells reduce tumour incidence by more than half in high-risk mouse models without autoimmunity, and persist for over a year in humans with an acceptable safety profile.
- Rationale: Cell therapies persist for years in some patients; logic gating and stress-ligand recognition have preclinical proof; prevention needs far fewer cells than treating bulk disease.
- Proposed test: Five-year preclinical programme with a go/no-go on incidence reduction and safety in two mouse models, then a phase 1 in Li-Fraumeni or Lynch carriers with persistence and safety endpoints.
- Maturity: speculative
- Actor: research

## Sources

- Bottleneck evidence (Dormant cells and minimal residual disease): Tie et al., ctDNA analysis guiding adjuvant therapy in stage II colon cancer (NEJM 2022): https://doi.org/10.1056/NEJMoa2200075

## Connected records

- technologies: [Armoured, logic-gated & next-gen CARs](https://onco.cc/technologies/armored-car/), [CAR-NK & CAR-macrophage](https://onco.cc/technologies/car-nk-macrophage/), [CAR-T cell therapy](https://onco.cc/technologies/car-t/), [TCR-T cell therapy](https://onco.cc/technologies/tcr-t/)
- targets: [BRCA1 / BRCA2 (HRD)](https://onco.cc/targets/brca/), [TP53](https://onco.cc/targets/tp53/)
- bottlenecks: [Cold tumours and the immunosuppressive microenvironment](https://onco.cc/bottlenecks/b-tme-immunosuppression/), [Dormant cells and minimal residual disease](https://onco.cc/bottlenecks/b-dormancy-mrd/), [Inherited risk is mostly unidentified](https://onco.cc/bottlenecks/b-hereditary-risk/)
- key papers: [Vogelstein, Lane and Levine 2000: surfing the p53 network](https://onco.cc/key-papers/paper-vogelstein-surfing-p53-network-nature-2000/)

---
JSON: https://onco.cc/api/v1/entities/idea-moon-engineered-immune-surveillance.json